Table 1 Patient demographics, clinical characteristics, and ECT treatment information.
Demographics | CLINICAL INFORMATION | ECT INFORMATION | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ID | Sex (M/F) | Age | Dx | QIDS | Antidepressant | Mood stabilizer | BZD | Antipsychotic | Stimulant | Tx # | Total Tx | Laterality | Pulse width (msec) | Stimulus (%) | Seizure (sec) | Anesthesia |
1 | FTM | 30 s | MDD, PTSD, Unspecified anxiety | 21 9 | DUL DUL | 1 8 | 10 10 | BL RUL | 0.3 0.5 | 10 50 | 300 117 | MTX, SUX MTX, SUX, Alfent, CAFF | ||||
2 | M | 50 s | MDD, PTSD, Alcohol use d/o | 20 17 | VEN VEN | Lithium Lithium | 1 3 | 3 3 | BL BL | 0.5 0.5 | 30 30 | 69 76 | MTX, SUX MTX, SUX | |||
3 | F | 40 s | MDD, PTSD, Eating d/o | 20 18 | FLU, BUP NTP | 1 7 | 9 9 | BL BL | 0.5 0.5 | 10 40 | 163 50 | MTX, SUX MTX, SUX, CAFF | ||||
4 | M | 60 s | MDD, Alcohol use d/o | 14 10 | MIR MIR | Quetiapine Quetiapine | 8 12 | 12 12 | BL BL | 0.5 0.5 | 75 100 | 38 36 | MTX, SUX, CAFF MTX, SUX, CAFF | |||
5 | M | 40 s | Bipolar II d/o, Polysubstance abusea | 11 9 | BUP, DUL BUP, DUL | Lurasidone Lurasidone | 4 12 | 12 12 | BL BL | 0.5 0.5 | 60 100 | 36 59 | MTX, SUX MTX, SUX, Alfent, CAFF, Glycopyr | |||
6 | M | 60 s | Bipolar II d/o, PTSD, Social anxiety | 18 8 | DUL DUL | Lorazepam Lorazepam | Ritalin Ritalin | 2 12 | 12 12 | RUL RUL | 0.5 0.5 | 60 90 | 35 21 | MTX, SUX, Alfent MTX, SUX, Alfent | ||
7 | M | 50 s | MDD, PTSD Alcohol use d/o | 22 20 15 | VEN VEN VEN | Quetiapine Quetiapine Quetiapine | 1 4 7 | 7 7 7 | BL BL BL | 0.5 0.5 0.3 | 30 50 100 | 25 134 18 | MTX, SUX MTX, SUX, Alfent MTX, SUX, Alfent, CAFF, KET | |||
8 | M | 30 s | MDD, PTSD, | 18 14 | FLU, MIR FLU, MIR | 1 4 | 10 10 | BL BL | 0.3 0.3 | 10 20 | 66 71 | MTX, SUX MTX, SUX | ||||
9 | M | 40 s | MDD, PTSD, Alcohol use d/o | 23 19 - 15 | DUL DUL DUL | Risperidone | 1 5 9 12 | 12 12 12 12 | BL BL BL BL | 0.3 0.3 0.5 0.5 | 5 10 80 100 | 130 40 64 43 | MTX, SUX MTX, SUX, Glycopyr MTX, SUX, Glycopyr MTX, SUX, Glycopyr | |||
